Pharmacotherapy for Parkinson's disease. (Q37016031)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

Pharmacotherapy for Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jack J Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

12 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

161S-173S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

Molecular pathophysiology of Parkinson's disease

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Oxidative stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Prevention and treatment of motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Using liquid levodopa in the treatment of Parkinson's disease. A practical guide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Safety of selegiline with cold medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

COMT inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Entacapone. A review of its use in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Tolcapone: a review of its use in the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

A review of the health-related quality of life and economic impact of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.161S

10.1592/PHCO.27.12PART2.161S

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18041936%20AND%20SRC:MED&resulttype=core&format=json